亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma

索拉非尼 医学 肝细胞癌 危险系数 内科学 实体瘤疗效评价标准 肝癌 肿瘤科 经导管动脉化疗栓塞 胃肠病学 随机对照试验 随机化 置信区间 肝功能 进行性疾病 化疗
作者
Masatoshi Kudo,Kazuomi Ueshima,Masafumi Ikeda,Takuji Torimura,Nobukazu Tanabe,Hiroshi Aikata,Namiki Izumi,Takahiro Yamasaki,Shunsuke Nojiri,Keisuke Hino,Hidetaka Tsumura,Teiji Kuzuya,Norio Isoda,Michihisa Moriguchi,Hajime Aino,Akio Ido,Naoto Kawabe,Kazuhiko Nakao,Yoshiyuki Wada,Sadahisa Ogasawara,Kenichi Yoshimura,Takuji Okusaka,Junji Furuse,Norihiro Kokudo,Kiwamu Okita,Philip J. Johnson,Yasuaki Arai
出处
期刊:Liver cancer [Karger Publishers]
卷期号:11 (4): 354-367 被引量:72
标识
DOI:10.1159/000522547
摘要

<b><i>Introduction:</i></b> Several clinical trials comparing the efficacy and safety of transarterial chemoembolization (TACE) plus molecular-targeted agents versus TACE alone revealed no clinical benefits in progression-free survival (PFS) or overall survival (OS). Here, we report the final OS analysis from the TACTICS trial, which previously demonstrated significant improvement in PFS with TACE plus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) (NCT01217034). <b><i>Methods:</i></b> Patients with unresectable HCC were randomized to a TACE plus sorafenib group (<i>N</i> = 80) or a TACE alone group (<i>N</i> = 76). Patients in the combination treatment group received sorafenib 400 mg once daily for 2–3 weeks before TACE, followed by 800 mg once daily during on-demand conventional TACE sessions until time to untreatable progression. In this trial, TACE-specific PFS was used. TACE-specific PFS is defined as the time from randomization to progressive disease (PD) or death from any cause, and PD was defined as untreatable progression, caused by the inability of a patient to further receive or benefit from TACE for reasons that include intrahepatic tumor progression (25% increase vs. baseline) according to response evaluation criteria in cancer of the liver, the detection of extrahepatic spread, vascular invasion, or transient deterioration of liver function to Child-Pugh C after TACE. <b><i>Results:</i></b> At the cut-off date of July 31, 2020, 131 OS events were observed. The median OS was 36.2 months with TACE plus sorafenib and 30.8 months with TACE alone (hazard ratio [HR] = 0.861; 95% confidence interval [CI], 0.607–1.223; <i>p</i> = 0.40, ΔOS, 5.4 months). The updated PFS was 22.8 months with TACE plus sorafenib and 13.5 months with TACE alone (HR = 0.661; 95% CI, 0.466–0.938; <i>p</i> = 0.02). Post-trial treatments with active procedures/agents were received by 47 (58.8%) patients in the TACE plus sorafenib group and 58 (76.3%) in the TACE alone group (<i>p</i> = 0.01). In post hoc analysis, PFS and OS benefit were shown in HCC patients with tumor burden beyond up-to-7 criteria. <b><i>Conclusions:</i></b> In TACTICS trial, TACE plus sorafenib did not show significant OS benefit over TACE alone; however, clinical meaningful OS prolongation and significantly improved PFS was observed. Thus, the TACE plus sorafenib can be considered a choice of treatment in intermediate-stage HCC, especially in patients with high tumor burden. Trial Registration: NCT01217034.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Ghiocel完成签到,获得积分10
1秒前
7秒前
佟语雪完成签到,获得积分10
7秒前
轻松的惜芹应助喂喂采纳,获得10
11秒前
淳于如雪发布了新的文献求助10
14秒前
LLL完成签到 ,获得积分10
18秒前
yar应助淳于如雪采纳,获得10
19秒前
Koking关注了科研通微信公众号
24秒前
25秒前
淳于如雪完成签到,获得积分20
27秒前
lv发布了新的文献求助10
28秒前
我是老大应助吴嘉俊采纳,获得10
31秒前
32秒前
在水一方应助阿九采纳,获得10
37秒前
37秒前
ZT完成签到,获得积分10
41秒前
搜集达人应助zhouleiwang采纳,获得10
42秒前
吴嘉俊发布了新的文献求助10
43秒前
仙人掌王朝完成签到,获得积分10
45秒前
48秒前
Hello应助zhouleiwang采纳,获得10
48秒前
阿九完成签到,获得积分10
51秒前
lllxxx完成签到 ,获得积分10
52秒前
lv发布了新的文献求助10
53秒前
冉亦完成签到,获得积分10
57秒前
WGS完成签到,获得积分10
58秒前
科研通AI2S应助科研通管家采纳,获得10
59秒前
华仔应助科研通管家采纳,获得20
59秒前
吉吉吉完成签到 ,获得积分10
1分钟前
1分钟前
阿九发布了新的文献求助10
1分钟前
大胆的小懒猪完成签到 ,获得积分10
1分钟前
111完成签到 ,获得积分10
1分钟前
1分钟前
yx_cheng应助001az采纳,获得30
1分钟前
1分钟前
miles完成签到,获得积分10
1分钟前
简单山水发布了新的文献求助10
1分钟前
Yina完成签到 ,获得积分10
1分钟前
友好胜完成签到 ,获得积分10
1分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990012
求助须知:如何正确求助?哪些是违规求助? 3532049
关于积分的说明 11256153
捐赠科研通 3270925
什么是DOI,文献DOI怎么找? 1805123
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809216